

## Your membership matters.

Continue to help lead the fight against kidney disease. Renew today.

www.asn-online.org/membership



CJASN

Clinical Journal of the  
American Society of Nephrology

HOME | CURRENT ISSUE | ADVERTISE | SUBSCRIBE | ARCHIVES | FEEDBACK | ALERTS | HELP

User Name

Password

LOG-IN

Search



Advanced Search

## A French Cohort Study of Kidney Retransplantation after Post-Transplant Lymphoproliferative Disorders

Sophie Caillard, Etienne Cellot, Jacques Dantal, Olivier Thauvat, François Provot, Bénédicte Janbon, Matthias Buchler, Dany Anglicheau, Pierre Merville, Philippe Lang, Luc Frimat, Charlotte Colosio, Eric Alamartine, Nassim Kamar, Anne Elisabeth Heng, Antoine Durrbach, Valérie Moal, Joseph Rivalan, Isabelle Etienne, Marie Noelle Peraldi, Anne Moreau, Bruno Moulin for the French PTLD Registry

[+](#) Author Affiliations

### Correspondence:

Prof. Sophie Caillard, Service de Néphrologie, 1 place de l'hôpital, 67091 Strasbourg, France. Email: [sophie.caillard@chru-strasbourg.fr](mailto:sophie.caillard@chru-strasbourg.fr)

S.C. and E.C. contributed equally to this work.

### Abstract

**Background and objectives** Post-transplant lymphoproliferative disorders arising after kidney transplantation portend an increased risk of morbidity and mortality. Retransplantation of patients who had developed post-transplant lymphoproliferative disorder remains questionable owing to the potential risks of recurrence when immunosuppression is reintroduced. Here, we investigated the feasibility of kidney retransplantation after the development of post-transplant lymphoproliferative disorder.

**Design, setting, participants, & measurements** We reviewed the data from all patients who underwent kidney retransplantation after post-transplant lymphoproliferative disorder in all adult kidney transplantation centers in France between 1998 and 2015.

**Results** We identified a total of 52 patients with kidney transplants who underwent 55 retransplantations after post-transplant lymphoproliferative disorder. The delay from post-transplant lymphoproliferative disorder to retransplantation was  $100 \pm 44$  months (28–224); 98% of patients were Epstein-Barr virus seropositive at the time of retransplantation. Induction therapy for retransplantation was used in 48 patients (*i.e.*, 17 [31%] patients received thymoglobulin, and 31 [57%] patients received IL-2 receptor antagonists). Six patients were also treated with rituximab, and 53% of the patients received an antiviral drug. The association of calcineurin inhibitors, mycophenolate mofetil, and steroids was the most common maintenance immunosuppression regimen. Nine patients were switched from a calcineurin inhibitor to a mammalian target of rapamycin inhibitor. One patient developed post-transplant lymphoproliferative disorder recurrence at 24 months after retransplantation, whereas post-transplant lymphoproliferative disorder did not recur in 51 patients.

**Conclusions** The recurrence of post-transplant lymphoproliferative disorder among patients who underwent retransplantation in France is a rare event.

Adult Antilymphocyte Serum Antiviral Agents Calcineurin  
Calcineurin Inhibitors Cohort Studies Epstein-Barr Virus Infections  
France Herpesvirus 4, Human Humans Immunosuppression  
kidney kidney transplantation Lymphoproliferative Disorders  
Mycophenolic Acid Neoplasm Recurrence, Local  
Receptors, Interleukin-2 Reoperation Rituximab thymoglobulin

Received April 7, 2017.

« Previous | Next Article »  
Table of Contents

### This Article

Published online before  
print August 2017, doi:  
10.2215/CJN.03790417  
CJASN October 06, 2017  
vol. 12 no. 10 1663–1670

» Abstract Free

Figures Only

Full Text

Full Text (PDF)

Supplemental Data

Article Usage Stats

Article Usage Statistics



### Services

Email this article to a  
colleague

Alert me when this article is  
cited

Alert me if a correction is  
posted

Similar articles in this journal

Similar articles in PubMed

Download to citation manager

[© Get Permissions](#)

[+ Citing Articles](#)

[+ Google Scholar](#)

[+ PubMed](#)

### Current Issue

March 07, 2018, 13 (3)



Alert me to new issues of  
CJASN

ONLINE SUBMISSION

AUTHOR RESOURCES

ABOUT CJASN

EDITORIAL BOARD

REPRINTS/PERMISSIONS

IMPACT FACTOR

MOST READ

MOST CITED

CJASN ePress

Updated on:  
March 9, 2018  
By Date / By Subject



Advertising Disclaimer


Accepted June 26, 2017.

Copyright © 2017 by the American Society of Nephrology

Copyright © 2018 by the American Society of Nephrology

Be a part of something  
innovative,  
influential  
and dynamic.

**Be a part of ASN.**



ASN members enjoy  
discounts on ASN's  
educational programs,  
subscriptions to ASN's  
publications, and more.

Join or renew today at  
[www.asn-online.org/membership](http://www.asn-online.org/membership)



Print ISSN: 1555-9041

Online ISSN: 1555-905X